HCV Treatment
Vertex to Test 12-Week Telaprevir for People with Favorable IL28B Gene Pattern
- Details
- Category: HCV Treatment
- Published on Friday, 28 October 2011 00:00
- Written by Vertex Pharmaceuticals
Vertex Pharmaceuticals this week announced the initiation of a new Phase 3b clinical trial (CONCISE) to test whether the recently approved hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) plus pegylated interferon/ribavirin can cure treatment-naive patients and prior relapsers with the favorable IL28B CC gene pattern in just 12 weeks.
HCV Polymerase Inhibitor Setrobuvir Looks Safe and Effective in Interim Analysis
- Details
- Category: HCV Treatment
- Published on Tuesday, 25 October 2011 00:00
- Written by Anadys
The investigational hepatitis C virus (HCV) polymerase inhibitor setrobuvir (ANA598) has demonstrated good efficacy to date in an ongoing Phase 2b trial, producing viral suppression in more than three-quarters of prior non-responders and relapsers. About 70% of treatment-naive patients were eligible for short-duration treatment based on early virological response.
IDSA 2011: Boceprevir Increases Hepatitis C Treatment Response for HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Tuesday, 25 October 2011 00:00
- Written by Liz Highleyman
The recently approved hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis) added to pegylated interferon/ribavirin significantly improved the likelihood of virological response at week 24 in HIV/HCV coinfected patients, according to a late-breaker presentation at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) in Boston.
EACS 2011: Predictors of HCV Viral Load in HIV/HCV Coinfected Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 25 October 2011 00:00
- Written by Liz Highleyman
Hepatitis C virus (HCV) RNA levels rise over time in HIV/HCV coinfected people, reducing the chances of sustained response to interferon-based treatment. But antiretroviral therapy may help control HCV viral load and contribute to higher likelihood of treatment success, according to a report presented at the 13th European AIDS Conference (EACS 2011) this month in Belgrade.
New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, and PrEP
- Details
- Category: HIV Treatment
- Published on Monday, 17 October 2011 00:00
- Written by Liz Highleyman
On October 14, 2011, the U.S. Department of Health and Human Services (DHHS) issued updated guidelines for the use of antiretroviral therapy in adults and adolescents.
The European AIDS Clinical Society (EACS) released revised guidelines the same day at the 13th European AIDS Conference in Belgrade.
The American Association for the Study of the Liver (AASLD) this month released new guidelines for the treatment of genotype 1 chronic hepatitis C, including information about boceprevir (Victrelis) and telaprevir (Incivek).
More Articles...
- AASLD Hepatitis C Treatment Guidelines Updated to Include Boceprevir and Telaprevir
- EACS 2011: People on Methadone Maintenance Can Be Successfully Treated for Hepatitis C
- FDA Approves Pegasys Autoinjector for Hepatitis C Patients
- Coffee Helps Reduce Side Effects in HIV/HCV Coinfected People during Interferon-based Therapy
Web Design and Development by